TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors
February 04, 2021 08:00 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies...
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
January 19, 2021 22:03 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies...
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
January 19, 2021 06:24 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies...
TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones
January 08, 2021 08:00 ET
|
TCR2 Therapeutics
- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21 - Identification of gavo-cel recommended Phase 2 dose and initiation of Phase 2 study expected in 2021 -...
TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference
December 21, 2020 08:00 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors
December 13, 2020 09:00 ET
|
TCR2 Therapeutics
- TC-210 induced tumor regression in all of the first eight patients - Ovarian cancer patient achieved confirmed RECIST partial response (PR) - Overall response rate (ORR) 50% in patients...
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
December 11, 2020 16:05 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients...
TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 12, 2020 06:45 ET
|
TCR2 Therapeutics
- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20 - Additional clinical sites to include UCSF Medical Center and Princess Margaret Cancer Centre in the...
TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity
November 10, 2020 08:00 ET
|
TCR2 Therapeutics
- ElevateBio BaseCamp to support anticipated TC-210 Phase 2 clinical trial demand CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...
TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
September 29, 2020 08:00 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...